Amerikanische Gesellschaft für Hirudotherapie

Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech

Basic science / preclinical published in Int J Mol Sci (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenomik & ProteomikSpeichel-PharmakologieArzneimittelentwicklungTolksdorf C et al. · International journal of molecular sciences, 2025

Abstract

Hematophagous leeches rely on a broad diversity of bioactive factors that interfere with the host's defense systems to secure a successful blood meal. The most prominent examples of such factors are the antithrombotics that address either the primary hemostasis (the platelet aggregation) or the secondary hemostasis (the blood coagulation). Whereas the inhibitors of platelet aggregation mainly cause continuous blood flow, coagulation inhibitors mainly keep the blood fluid within the stomach of the leech. The critical dependency of hematophagous leeches on the accurate action of all antithrombotic factors may explain the presence of multiple genes for each type of these factors that is regularly observed in leech genomes. The genome of Hirudinaria manillensis Lesson, 1842, the Asian buffalo leech, contains five individual genes that encode variants of the coagulation inhibitor hirudin. However, no genes that encode putative decorsins, the archetype of leech-derived inhibitors of platelet aggregation, have been described to date. Here, we report the identification of one monomeric and four multimeric decorsin encoding genes in the genome of H. manillensis. A selection of the putative decorsins was expressed as recombinant proteins, purified and functionally characterized. All but one of these putative decorsins displayed platelet aggregation-inhibitory potencies. Furthermore, we provide a mathematical calculation based on the mechanism of alternative pre-mRNA splicing that illustrates the potential to generate an enormous variety of different factors from one single multimeric ornatin gene.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsLeechesPlatelet AggregationAmino Acid SequenceHirudinsPhylogenyPlatelet Aggregation InhibitorsRecombinant Proteins

Zusammenfassung

Identification of one monomeric and four multimeric decorsin-encoding genes in Hirudinaria manillensis (Asian buffalo leech). Recombinant expression and functional verification of platelet-aggregation inhibition; mathematical model of alternative splicing diversity.

Warum dies für die Hirudotherapie relevant ist

This study identified one monomeric and four multimeric decorsin-encoding genes in the genome of Hirudinaria manillensis (Asian buffalo leech), a species previously known to encode hirudin variants but not decorsins — the archetypal leech-derived platelet aggregation inhibitors. Selected putative decorsins were expressed as recombinant proteins, purified, and functionally characterized; all but one displayed platelet aggregation-inhibitory activity. The authors also mathematically modeled how alternative pre-mRNA splicing of multimeric ornatin genes could generate extensive molecular diversity. This work directly advances understanding of the leech secretome's antithrombotic repertoire and its genetic basis, core to ASH's domain. Caveat: Findings are preclinical, based on in vitro recombinant protein characterization; no clinical or in-vivo leech therapy data are presented.

Zitation

Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech.

Tolksdorf C et al. · International journal of molecular sciences, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.